All Duchenne Muscular Dystrophy articles

  • AdobeStock_207448226
    CPD Supplement

    Qualification of stride velocity endpoint in Duchenne Muscular Dystrophy

    2021-10-01T10:39:00Z

    In April 2019, the Committee for Medicinal Products for Human Use (CHMP) issued a qualification opinion on stride velocity as an endpoint in clinical studies of medicines for the treatment of Duchenne Muscular Dystrophy (DMD).[1] Mutations in the dystrophin gene cause this inherited, x-linked disorder which causes progressive muscle weakness ...